2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
24
Carcinoma, Non-Small-Cell Lung
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Pancreatic Neoplasms
5
Neoplasms
5
Lung Neoplasms
5
Leukemia, Myeloid, Acute
5
Triple Negative Breast Neoplasms
4
Melanoma
4
Leukemia, Myelomonocytic, Chronic
4
Carcinoma, Renal Cell
4
Breast Diseases
4
Urinary Bladder Neoplasms
3
Thoracic Neoplasms
3
Respiratory Tract Neoplasms
3
Lymphoma
3
Lung Diseases
3
Leukemia, Myelomonocytic, Acute
3
Kidney Neoplasms
3
Fallopian Tube Neoplasms
3
Congenital Abnormalities
3
Colonic Neoplasms
3
Bronchial Neoplasms
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Sezary Syndrome
2
Recurrence
2
Rectal Neoplasms
2
Interventions
Pemetrexed
9
Nivolumab
8
Cisplatin
8
Carboplatin
8
pembrolizumab
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Drug Therapy
4
Cyclophosphamide
4
ribociclib
3
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Mitomycin
3
Docetaxel
3
Cetuximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
entinostat
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled